REG - Victrex PLC - Directorate Change

VictrexAnnouncement

15/03/2024 08:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240315:nRSO0292Ha&default-theme=true

RNS Number : 0292H  Victrex PLC  15 March 2024

 

15 March 2024

Victrex plc - Directorate change

Victrex appoints Urmi Prasad Richardson as a non-executive director

Victrex plc is an innovative world leader in high performance polymer
solutions, delivering sustainable products which enable environmental and
societal benefit in multiple end-markets. The Group is pleased to announce
that Urmi Prasad Richardson has been appointed as a non-executive director of
the Board, effective from 1(st) May 2024.

Commenting on the appointment:

Dr Vivienne Cox DBE, Chair of Victrex, said: "I am delighted to welcome Urmi
to the Victrex Board. She brings a wealth of relevant experience across a
number of global companies, with an emphasis on medical, science-based
innovation, clinical scalability and healthcare. Medical is a key part of the
Victrex Group and one where we have made good progress in starting to unlock
its true potential. Our products support improved clinical outcomes and our
goal is to double revenues in our Medical business over the next five years.

 

"Victrex has faced challenging trading conditions over the past year, in line
with the wider Chemical sector. However, with a wealth of growth
opportunities, high levels of innovation and well invested assets, the Board
remains focused on the delivery of our strategy."

 

Career history:

Urmi has a wealth of global experience in executive and non-executive roles
over a 25 year period. She has a particular focus on science, medical and
innovation based businesses. Urmi is currently President EMEA of Thermo Fisher
Scientific, a world leader in serving science, with products which help
accelerate life science research and improve patient health. Her executive
career includes roles at The Linde Group, where she was Global Head of
Healthcare, at Novartis and Foundation Medicine (a Roche company). She started
her career with G.D. Searle (a Pfizer company) and has worked throughout
Europe and the US. Urmi has extensive experience in strategy, business
development and product commercialisation in Europe, Asia and North America.

 

Urmi holds a number of advisory Board roles at unlisted organisations in the
sectors of longevity, blockchain, and targeted therapy in oncology. Her
previous non-executive roles include Linde Healthcare.

 

There is no further information to be disclosed under Listing Rule 9.6.13.

 

 

Victrex plc:

 

Andrew Hanson, Director of Investor Relations, Corporate Communications &
ESG
 
 

+44 (0) 1253 898121

+44 (0) 7809 595831

 

 

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions,
focused on the strategic markets of Automotive, Aerospace, Energy &
Industrial, Electronics and Medical. Every day, millions of people rely on
products or applications which contain our sustainable materials, from
smartphones, aeroplanes and cars to energy operations and medical devices.
'Polymer & Parts' - with over 40 years' experience, we are moving beyond
the polymer into semi-finished and finished products which shape future
performance for our customers and our markets, enable environmental and
societal benefit for our customers and drive value for our shareholders. Find
out more at www.victrexplc.com (http://www.victrexplc.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAXDSFSDLEEA